Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Based on Molecular Subtypes
NCT07503639Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Small Molecules
01
Overview
A Phase 2 trial of retlirafusp alfa, CS1002, adebrelimab, cetuximab, HRS-7058 in colorectal cancer (CRC), sponsored by Fudan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfaCS1002adebrelimabcetuximabHRS-7058
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07503639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503639.